Alzheimer's Disease, Dementia & Brain Health Newsletter
October 2026
| | |
The Shifting Drug Pipeline: Moving Beyond Amyloid
For decades, Alzheimer’s treatments focused almost exclusively on removing amyloid plaques. However, the global clinical trial pipeline reveals a massive scientific evolution. Right now, researchers are evaluating 158 medicines across 192 active clinical trials.
Amyloid-targeting drugs now make up only 20% of the research pipeline. The remaining 80% focuses on non-amyloid pathways, including reducing chronic brain inflammation, regulating the brain's immune cells, and targeting tau proteins. For families, this means a future filled with diversified, combination therapies tailored to how the disease uniquely progresses in each individual.
| |
Blood Tests May Help Predict Alzheimer’s Risk
The landscape of dementia diagnostics is experiencing a monumental shift away from traditional, invasive spinal taps and expensive imaging. Recent findings presented at medical conferences reveal that high-accuracy blood tests tracking the p-tau217 protein biomarker can now identify the biological roots of Alzheimer's with incredible precision. When physicians incorporate these tests, their diagnostic accuracy surges from 65% to 93%.
Beyond improving care, data published in the Journal of the American Medical Association (JAMA) indicates these blood tests can forecast future cognitive impairment risk. Healthy older adults found to have elevated p-tau217 baseline levels carry a 38% risk of developing early signs of dementia within five years, and a 78% risk over a decade. These predictive powers are transforming how clinical trials enroll volunteers, opening the door to targeted, preventative interventions years before physical symptoms manifest.
While medical experts emphasize that routine testing for asymptomatic individuals is not yet standard clinical practice, this technology represents a giant leap toward accessible, early-stage neurological screening.
| | |
Parkinson's Disease: Environmental Triggers
Recent scientific reports show that exposure to environmental toxins like certain pesticides and air pollution increase risk for Parkinson's disease. While some people inherit genes that increase their risk, experts at the Michael J. Fox Foundation explain that outside pollutants often trigger the illness. One major threat comes from a common weedkiller called paraquat, which is banned in many countries but still in common use in the United States. According to the American Brain Foundation, exposure to paraquat can raise a person's risk of developing this brain condition by 150%. Exposure to Trichloroethylene (TCE), a harsh liquid used in dry cleaning and metal degreasing, may also increase risk. To protect your brain health, the Parkinson's Foundation recommends avoiding these toxic chemicals, exercising regularly and indoors on high pollution days to reduce air pollution exposure, and drinking filtered water.
| | |
Caring at Home
Alzheimer’s disease and other dementias often gradually affect everyday activities, making once simple routines more challenging and increasing the need for support and patience from care partners. Tasks that once felt automatic like brewing a morning cup of coffee, buttoning a shirt, or navigating a familiar grocery store can become sources of frustration, confusion, or anxiety for those living with dementia.
As care partners, watching these changes unfold requires a deep shift in how we approach the day. It calls for us to slow down, break steps into smaller pieces, and find meaning not just in the completion of a task, but in the moments of connection shared along the way. Learn more about practical strategies for adapting daily routines, minimizing stress, and bringing a sense of comfort, predictability, and dignity back to everyday life.
| | |
HHS Alzheimer’s Summit and NAPA Advisory Council
Monday, October 19, 2026
The next meeting of the Advisory Council on Alzheimer's Research, Care, and Services will be held in conjunction with the U.S. Department of Health and Human Services (HHS) Alzheimer’s Disease and Related Dementias Summit on Monday, October 19, 2026. The Summit will take place from 9:30am to noon ET. The Advisory Council meeting will be held from 1:00 to 5:00pm ET and will be hybrid, with both in-person and virtual participation.
Public Input: Time will be allocated on the agenda to hear public comments from 3:30pm to 3:55pm. Oral comments will be limited to two (2) minutes per individual. Individuals who wish to provide an oral public comment must register using the registration form no later than Monday, October 12.
Registered commenters participating virtually will receive a meeting link and dial-in number and may use either option to join the meeting. Individuals may also request that NAPA staff read their comments during the public comment session. To make this request, please select the applicable response on the registration form and email the comment to napa@hhs.gov with the subject line “October 19 Public Comments Reading Request.” Comments to be read by NAPA staff must be received by Monday, October 12.
| | |
Walk With Me
Thursday, November 12
7:00p.m.
Made Here, a curated film series presented by Vermont PBS, showcases the best locally-based content from Vermont, Montreal, Upstate New York, and Northern New England presents, Walk With Me.
Walk With Me is an acclaimed independent documentary film directed by filmmaker and casting director Heidi Levitt. It tells the deeply personal story of her husband, Charlie Hess, who was diagnosed with early-onset Alzheimer’s disease at age 57. Filmed over four years, the documentary is a tender portrait of their marriage adapting to the challenges of cognitive decline, serving as both an exploration of caregiving and a love letter to the community of Stowe, Vermont, where they split their time.
| | |
Did someone share this email with you? Sign-up to subscribe to this newsletter.
Alzheimer's Disease and Healthy Aging Program
October 2026
| | | | |
